Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 7/20 | 0.50 |
| ▸ | HTR7 | P34969 | 7/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13499437 | 0.88 | TMEM97 (0.47) | HTR1AHTR7TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13499492 | 0.85 | HRH3 (0.48) | TMEM97SIGMAR1KCNH2MCHR1LTA4H | |
| SCHEMBL13499258 | 0.82 | HTR1A (0.48) | HTR1AHTR7TMEM97SIGMAR1KDM1A | |
| SCHEMBL13499322 | 0.79 | TMEM97 (0.53) | HTR1AHTR7TMEM97SIGMAR1KDM1A | |
| SCHEMBL13499330 | 0.79 | HTR1A (0.49) | HTR1AHTR7TMEM97SIGMAR1KDM1A | |
| SCHEMBL13499369 | 0.77 | HTR1A (0.48) | HTR1AHTR7TMEM97SIGMAR1KDM1A | |
| SCHEMBL6081709 | 0.76 | TMEM97 (0.69) | TMEM97SIGMAR1KCNH2MCHR1LTA4H | |
| SCHEMBL13499365 | 0.76 | HTR1A (0.50) | HTR1AHTR7TMEM97SIGMAR1KDM1A | |
| SCHEMBL1728694 | 0.74 | KDM4E (0.56) | SIGMAR1KCNH2MCHR1LTA4HKDM4E | |
| SCHEMBL1728503 | 0.74 | LTA4H (0.54) | TMEM97SIGMAR1KCNH2MCHR1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. | 2010-02-04 | — | — | US | disclosed |
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, ADRB2, CHRNA5 | HTR1A 155/4885HTR7 306/4885TMEM97 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.